MBAL Dr. Ivan Seliminski - Sliven AD

The Cardiology Department at MBAL Dr. Ivan Seliminski - Sliven AD focuses on innovative strategies to manage atherosclerotic cardiovascular disease and bleeding complications related to anticoagulant therapy. Trials aim to improve surgical outcomes for patients on FXa inhibitors and to evaluate new lipid‑modifying agents that may lower the risk of major adverse CV events.

• Reversal of anticoagulation for urgent surgery
• Evaluation of obicetrapib on cardiovascular event reduction
• Optimization of lipid‑modifying therapy in ASCVD

With 13 investigators conducting four trials, the site contributes valuable data to cardiovascular research in Europe.

Research in the respiratory area targets persistent asthma that remains uncontrolled despite standard treatment. Studies assess novel inhaled anti‑inflammatory compounds as an add‑on therapy to existing ICS/LABA regimens, seeking to reduce the frequency of asthma exacerbations over a year‑long period.

• Add‑on inhaled therapy to improve asthma control
• Reduction of asthma exacerbation rates
• Safety assessment of new inhaled anti‑inflammatory agents

The department’s multidisciplinary team supports patients in Sliven and the wider Bulgarian region.

The site is actively involved in pediatric investigations of emerging antiviral treatments for COVID-19. Trials evaluate the pharmacokinetics and safety of a novel antiviral in children and adolescents, aiming to fill the therapeutic gap for young patients affected by the virus.

• Pharmacokinetic profiling of antiviral in pediatric participants
• Safety and tolerability assessment in children with COVID‑19
• Development of age‑appropriate treatment options

These studies enhance global knowledge of pediatric COVID‑19 management while leveraging the expertise of the local clinical team.